Umoja Biopharma delayed its first clinical readout from an in‑vivo CAR‑T trial, citing program timing changes, while academic teams reported preclinical data for next‑generation CAR‑T constructs that produced potent antitumor responses with fewer toxic effects in mouse models. Umoja remains well‑capitalized but pushed out its China trial timeline for further data preparation. Researchers at USC described ZAP327‑signaling domain CARs that matched approved CAR‑T potency in mice and reduced toxicity markers, offering a potential path to safer therapies for blood and solid tumors. The juxtaposition underscores both the promise and operational complexity of advancing CAR‑T modalities from preclinical to clinical stages.